Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Work In Process (2016 - 2018)

Amicus Therapeutics (FOLD) has disclosed Work In Process for 3 consecutive years, with $7.2 million as the latest value for Q1 2018.

  • For the quarter ending Q1 2018, Work In Process rose 107.46% year-over-year to $7.2 million, compared with a TTM value of $7.2 million through Mar 2018, up 107.46%, and an annual FY2017 reading of $3.8 million, up 16.17% over the prior year.
  • Work In Process was $7.2 million for Q1 2018 at Amicus Therapeutics, up from $3.8 million in the prior quarter.
  • Across five years, Work In Process topped out at $7.2 million in Q1 2018 and bottomed at $137000.0 in Q2 2016.
  • Average Work In Process over 3 years is $4.0 million, with a median of $3.6 million recorded in 2017.
  • Peak annual rise in Work In Process hit 2643.07% in 2017, while the deepest fall reached 16.17% in 2017.
  • Year by year, Work In Process stood at $3.3 million in 2016, then grew by 16.17% to $3.8 million in 2017, then skyrocketed by 87.48% to $7.2 million in 2018.
  • Business Quant data shows Work In Process for FOLD at $7.2 million in Q1 2018, $3.8 million in Q4 2017, and $6.9 million in Q3 2017.